ReviewFrontiers in oncology2026
Comedication that increase the risk of cisplatin-induced hearing loss in pediatric cancer patients: a narrative literature review and meta-analysis.
Review in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Cisplatin induced hearing loss (CIHL) affects 50-70% of all cisplatin-treated children. Cisplatin containing regimens often include various supportive care drugs and chemotherapeutic agents. No structured overview is available of the potential impact of concomitant medication, administered alongside cisplatin, on the increased risk of CIHL. Methods: A narrative review, based on a PubMed (Medline), EMBASE, and Cochrane CENTRAL search, was conducted to summarize the effect of concomitant chemotherapeutic agents and supportive care drugs on developing hearing loss in cisplatin-treated pediatric cancer patients. The studies were categorized according to type of comedication. Results: Our review identified 27 relevant studies with a total of 7007 patients. There is heterogeneity among the included studies with respect to design and quality. Nevertheless, the results of the meta-analyses showed that vincristine (OR: 3.80, 95% CI: 2.86-5.04), furosemide (OR: 1.63, 95% CI: 1.14-2.33), aminoglycosides (OR: 1.72, 95% CI: 1.14-2.60) and vancomycin (OR: 1.63, 95% CI: 1.09-2.45) were recurrently found to be associated with an increased risk of CIHL. Conclusion: This review represents the first comprehensive overview of evidence on the contribution of comedication to the risk of CIHL. Vincristine, furosemide, ahminoglycosides, and vancomycin are associated with an increased risk of CIHL in pediatric cancer patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.